Disclosed herein is a lag time delayed-release combination pharmaceutical composition comprising of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor, as well as a preparation method thereof. The composition is designed based on chronotherapy in which active ingredients are administered to have different onset times, such that the release of each active ingredient of the composition in body can be lag time delayed to a specific rate. Also, the composition is very effective for the treatment of hypertension and the prevention of complications in patients having metabolic syndromes which show diabetes, obesity, hyperlipidemia, coronary artery diseases and the like. More specifically, the composition is a drug delivery system designed such that the release of each drug is controlled to a specific rate, and it can show the most ideal effect, when it is absorbed in body.

Kim; Sung Wuk

Jun; Sung Soo

Jo; Young Gwan

Koo; Ja Seong

Son; Jae Woon

Hanall Biopharma Co., Ltd.

Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors

The cell surface c-Met receptor, through which hepatocyte growth factor (HGF) signals are mediated, has now been identified as the Angiotensin-IV receptor (AT(4)R) in processes that include HGF-regulated cell motility, angiogenesis, cancer metastasis, adipogenesis and others. Disclosed are angiotensin-like factor compositions and methods for using them to diagnose, prevent and/or treat conditions associated with c-Met dysregulation, including cancer, obesity and conditions associated with obesity, and other disorders, for example, by altering hepatocyte growth factor activity or c-Met receptor activity by administering an angiotensin-like factor that specifically binds to a cell surface c-Met receptor.

Washington State University Research Foundation

C-Met receptor regulation by angiotensin IV (AT.sub.4) receptor ligands

Angiotensin-like factor compositions and methods for using them to diagnose, prevent and/or treat conditions associated with c-Met dysregulation, are provided. The conditions include cancer, obesity, conditions associated with obesity, and neurodegenerative diseases such as general dementia, Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, traumatic brain injury and spinal cord trauma.

Harding; Joseph W.

Wright; John W.

Elias; Patrick D.

Yamamoto; Brent J.

Kawas; Leen H.

Washington State University

C-Met receptor regulation by angiotensin IV (AT4) receptor ligands

Provided herein are small molecule agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions. The present invention is based on the seminal discovery of a series of potent small molecule agonists of the apelin receptor, which are useful for the treatment of diseases including heart failure, chronic kidney disease, hypertension, and metabolic disorders such as insulin resistance/diabetes and obesity. The compounds disclosed herein are highly specific for the apelin receptor versus the angiotensin II receptor (ATI).

angiotensin/lihavuus

Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors

C-Met receptor regulation by angiotensin IV (AT.sub.4) receptor ligands

C-Met receptor regulation by angiotensin IV (AT4) receptor ligands

Agonists of the apelin receptor and methods of use thereof

Täydellisin lääketieteellinen tietokanta tieteen tukemana